ANALYSIS OF CLINICAL EXAMPLES WHEN USING LNG-IUS
https://doi.org/10.21518/2079-701X-2017-13-43-49
Abstract
The use of long-acting contraceptive methods of the Long-Acting Reversible Contraception (LARC), to which the LNG-IUS belongs, with adequate and rational counseling can exercise not only a contraceptive, but also a preventive task in the treatment of disseminated gynecological diseases. Three clinical cases with the analysis of errors in the management of the patients are considered.
About the Authors
A. L. Tikhomirov
Evdokimov Moscow State Medical and Stomatologic University
Russian Federation
Russian Federation
MD, Prof.,
Moscow
S. I. Sarsania
Federal Reproduction Center Santa-Maria
Russian Federation
Moscow
Russian Federation
Moscow
I. B. Manukhin
Evdokimov Moscow State Medical and Stomatologic University
Russian Federation
Russian Federation
MD, Prof.,
Moscow
V. V. Kazenashev
Evdokimov Moscow State Medical and Stomatologic University
Russian Federation
Russian Federation
MD,
Moscow
T. A. Yudina
Multi-Profile Medical Holding SM-Klinika
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Cleland J. Contraception in historical and global perspective. Best Pract Res Clin Obstet Gynaecol, 2009, 23(2): 165–76.
2. Peipert JF, Zhao Q, Allsworth JE et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol, 2011, 117(5): 1105–13.
3. WHO (2004). Intrauterine devices (IUDs)». Medical Eligibility Criteria for Contraceptive Use (3rd ed.). Geneva: Reproductive Health and Research, WHO.
4. Lewis RA, Taylor D, Natavio MF et al. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception, 2010, 82: 491–6.26.
5. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception, 2007, 75(Suppl. 6): S16–S30.
6. Wilcox AJ, Weinberg CR, Armstrong EG, Canfield RE. Urinary human chorionic gonadotropin among intrauterine device users: detection with a highly specific and sensitive assay. Fertil Steril, 1987, 47(2): 265–9.
7. Margolis MB, Zieman M, Cohen J et al. The Myths and Facts of Intrauterine Contraception Bleeding Profiles. OBG Management. The Female Patient, 2011, Suppl. 1: 1–8.
8. Heikinheimo O, Inki P, Schmelter T, GemzellDanielsson K. Bleeding pattern and user satisfaction in second consecutive levonorgestrel releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod, 2014, 29(6): 1182–8.
9. Геворкян М.А., Манухин И.Б. Контрацептивные и лечебные преимущества внутриматочной левоноргестрел-рилизинговой системы «Мирена». РМЖ, 2008, 22(4): 31-6.
10. Кузнецова И.В. Внутриматочная гормональная контрацепция без эстрогенов. Гинекология, 2013, 15(6): 70-4.
11. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception, 2007, 75(Suppl. 6): S70–75.
12. Sherman CA, Harvey SM, Noell J. Are they still having sex? STI’s and unintended pregnancy among midlife women. J Women Aging, 2005, 17(3): 41–55.
Review
For citations:
Tikhomirov AL, Sarsania SI, Manukhin IB, Kazenashev VV, Yudina TA. ANALYSIS OF CLINICAL EXAMPLES WHEN USING LNG-IUS. Meditsinskiy sovet = Medical Council. 2017;(13):43-49. (In Russ.) https://doi.org/10.21518/2079-701X-2017-13-43-49
Views:
552
Email this article 